Cited by 107RNA Interference and Gene DeliveryRetinal Development and DisordersAdvanced Drug Delivery Systems

Nanoparticle-based technologies for retinal gene therapy

Open access
Adijanto, Jeffrey, Naash, Muna I.·2015·European Journal of Pharmaceutics and Biopharmaceutics

Abstract

For patients with hereditary retinal diseases, retinal gene therapy offers significant promise for the prevention of retinal degeneration. While adeno-associated virus (AAV)-based systems remain the most popular gene delivery method due to their high efficiency and successful clinical results, other delivery systems, such as non-viral nanoparticles (NPs) are being developed as additional therapeutic options. NP technologies come in several categories (e.g., polymer, liposomes, peptide compacted DNA), several of which have been tested in mouse models of retinal disease. Here, we discuss the key biochemical features of the different NPs that influence how they are internalized into cells, escape from endosomes, and are delivered into the nucleus. We review the primary mechanism of NP uptake by retinal cells and highlight various NPs that have been successfully used for in vivo gene delivery to the retina and RPE. Finally, we consider the various strategies that can be implemented in the plasmid DNA to generate persistent, high levels of gene expression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejpb.2014.12.028

Cites

237 of 237 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

3 of the 240 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Adijanto, J., & Naash, M. I.
Affiliations
University of Oklahoma Health Sciences Center (US)
Corresponding author
Naash, Muna I.
Venue
European Journal of Pharmaceutics and Biopharmaceutics
Publisher
Elsevier BV
Published
2015-09
Volume
95
Issue
Pt B
Pages
353-367
ISSN
0939-6411 (ISSN-L)
OpenAlex
W2045435902
Cited by
107
References
240
Citations by year
2026: 4 · 2025: 12 · 2024: 9 · 2023: 6 · 2022: 12 · 2021: 14 · 2020: 6 · 2019: 13 · 2018: 8 · 2017: 11 · 2016: 4 · 2015: 8
FWCI
1.00
Type
journal article
Language
en
Open access
Locations
  • European Journal of Pharmaceutics and Biopharmaceutics (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institutes of Health (EY18656, EY022778)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords
retinal gene therapy, nanoparticle-mediated gene delivery, inherited retinal disease, retinal degeneration, adeno-associated virus vectors, liposomes, nanoparticle uptake, endosomal escape, nuclear delivery, retinal pigment epithelium, persistent gene expression, plasmid DNA
MeSH terms
Animals, Disease Models, Animal, DNA, Gene Expression Regulation, Humans, Retina, Retinal Diseases, Genetic Therapy, Gene Transfer Techniques, Nanotechnology, Mice, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review